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The favourable effect of Helicobacter pylori eradication
therapy in patients with recurrent angina-like chest





I In nt tr ro od du uc ct ti io on n: :   The outcome of Helicobacter pylori (Hp) eradication therapy from
the aspect of prevention of chest pain recurrence is still uncertain. The aim of
this study was to assess the influence of Hp eradication therapy on the risk of
hospitalization due to acute coronary syndrome.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   The analysis was carried out in 63 consecutive patients
with recurrent retrosternal symptoms: 28 (44%) with significant coronary artery
narrowing in coronarography not qualified for revascularization by an invasive
cardiologist, and 35 (56%) with no obstructive coronary artery lesions. In 33
(52%) of the patients, Hp infection was found and standard eradication therapy
with omeprazole (2 ￗ 20 mg), amoxicillin (2 ￗ 1 g) and metronidazole (2 ￗ 500 mg)
was recommended. The mean follow-up period was 977 ﾱ249 days. 
R Re es su ul lt ts s: :   Chest pain requiring hospitalization because of unstable angina within
the follow-up period was observed in 9 (27%) of the Hp-infected individuals and
in 15 (50%) subjects in whom a urease test and histology did not confirm this
infection (p = 0.055). The recommendation of Hp-eradication treatment was
a significant factor prolonging the hospitalization-free period, both in the two
Kaplan-Meier curve analyses (Cox’s F test = 1.96; p = 0.049) and the Cox
proportional hazard model (beta = –1.18; p = 0.045), but was weaker than 
the effect of the non-obstructive coronary angiogram (beta = –1.45; p = 0.03). 
C Co on nc cl lu us si io on ns s: :   The recommendation of Hp-eradication therapy may prolong 
the hospitalization-free period for patients with recurrent chest pain. 
K Ke ey y   w wo or rd ds s: :   Helicobacter pylori, eradication therapy, chest pain, angina pectoris. 
Introduction 
Helicobacter  pylori  (Hp)  infection  has  been  suspected  of  being
a pathogenic  factor  in  many  diseases.  However,  its  important
pathophysiological role has been confirmed in only a few diseases of the
upper digestive tract and recently also for haematological abnormalities
(thrombocytopenic purpura and sideropenic anaemia) [1]. Helicobacter
pylori is a frequent cause of gastric and duodenal ulcers and dyspepsia,
as well as oesophageal motility disorders via its effects on the balance of
the autonomic nervous system [2]. Helicobacter pylori infection has also
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been recognized as a factor both in diminishing and
increasing the risk of gastro-oesophageal reflux
disease (GERD), the most frequent cause of non-
cardiac chest pain (NCCP) [3, 4]. The protective
effect of this microorganism on the course of GERD
has been explained by: (1) the induction atrophy of
gastric corpus mucosa, secondary hypochlorhydria,
and a reduction in oesophageal mucosa exposure
to acid; (2) the greater antacid effect of the proton
pump inhibitor (PPI) [5, 6]; and (3) a reduction in
oesophageal  inflammation  by  an  increase  in
sympathetic tone and vagal activity [2, 4]. The
potential harmful influence of Hp infection on the
course of GERD results from its stimulating effect
on  the  cytokines  and  the  synthesis  of  other
inflammatory mediators. These seem to be more
important in the pathogenesis of oesophagitis than
oesophageal mucosa exposure to acid [7]. The
above-mentioned role of Hp infection in GERD,
oesophageal motility disorders, and gastric and
duodenal ulcers pathogenesis may also potentially
concern the recurrent chest pain originating from
the  digestive  tract,  which  is  a very  important
problem in health care [8-10]. 
However, Hp infection may play a potential role
in the pathogenesis of chest pain, not only in
individuals with normal coronary angiogram (NCCP)
with cardiac syndrome X, but also in patients with
coronary artery disease (CAD), both as a promotion
effect of atherosclerotic plaque progression and
instability, and as a result of the overlapping of the
cardiac and upper digestive tract diseases observed
in more than 30% of subjects [11-13]. The role of Hp
infection in atherosclerosis complication evokes
some doubts, but some epidemiological studies
have  shown  that  CagA  seropositivity  was
significantly and positively associated with the
occurrence of acute coronary events, atherosclerosis
progression and arrhythmia prevalence [13-18]. The
positive relationship of Hp infection with cardiac
syndrome X [19, 20] has also been reported but not
confirmed by others [21, 22], whereas Sandifer et
al., based on the results of the EUROGAST Study
Group, have shown a negative association between
the seroprevalence of antibodies to Hp and the
death rate from ischaemic heart disease [23]. 
A number of mechanisms for the influence of
Hp on atherosclerosis complications have been
suggested. It may act directly on atherosclerotic
plaques, as suggested by the results of Kowalski et
al.,  who  revealed  the  presence  of  Hp  DNA  in
atherosclerotic plaques and an increase in coronary
artery diameter after microorganism eradication
[24, 25]. It was also implied that mimicry occurred
between the cytotoxin-associated gene-A (CagA)
antigen expressed by some Hp strains and the
protein present in atherosclerotic plaques [13].
Helicobacter pylori infection, similarly to periodontal
infection [26] or hepatitis C virus [27], may also act
as one among a number of factors taking part in
the mechanisms of pathogen burden through the
following:  non-specific  inflammatory  pathway
stimulation (e.g. hsCRP increase); the induction of
endothelial and microvascular dysfunction; an
increase in adhesion molecule expression (e.g.
VCAM-1, ICAM-1); the over-synthesis of cytokine
(e.g. IL-1β, IL-6, TNF-α); changes in the autonomic
nervous system balance [2, 28, 29]; and the pro  -
duction  of  metabolic  changes,  such  as  hyper  -
triglyceridaemia, increased LDL cholesterol level,
lipid  oxidation,  hyperfibrinogenaemia,  altered 
blood coagulation and leukocytosis [20]. The role
of Hp infection has also been reported as a cause
of myocarditis and ECG changes in patients with
persistent chest pain [30]. 
In considering that Hp infection may cause chest
pain  originating  both  from  the  heart  and  the
oesophagus, both with and without obstructive
lesions in a coronary angiogram, I have compared
the 2.7-year follow-up course of recurrent chest
pain  in  patients  infected  with  Hp  in  whom
eradication  therapy  was  recommended,  with
subjects in whom this infection had not been
diagnosed.  To  my  knowledge,  this  is  the  first
preliminary report to try to explain the role of Hp
in patients with recurrent chest pain of suspected
noncardiac origin and non-responsive to empirical
therapy with a proton pump inhibitor (PPI). 
Material and methods
This  analysis  was  carried  out  in  all  of  the 
63 consecutive patients diagnosed in 2004-2006
because of recurrent angina-like chest pain defined
as  follows:  precordial  symptoms  induced  by
exercise and receding after rest or taking nitro  -
glycerine. All subjects were referred for gastro  -
enterological  diagnosis  after  cardiac  work-up
(history, physical examination, resting ECG, echo  -
cardiography, treadmill stress test, and coronary
angiogram), and failed empirical therapy with PPIs.
The origin of the chest pain being non-cardiac in
character was suspected by the leading doctor,
independently of the researcher, because of its
recurrent course, resistance to treatment aimed at
coronary reserve improvement, and the lack of
signs of myocardial ischaemia in non-invasive
examinations. Twenty-eight (44%) patients had
significant lesions, with > 50% of the coronary
vessels  narrowing  but  not  being  qualified  for
revascularization by the invasive-cardiologist (CAD
group), and 35 (56%) subjects revealed either
a normal coronary angiogram or no obstructive
lesions. All the subjects fulfilled the inclusion
criteria: (1) aged between 40 and 70; (2) prior
coronary angiography performance; (3) angina-like
chest pain to the degree of class II or greaterArch Med Sci 1, February / 2011 75
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according to the Canadian Cardiovascular Society
(CCS);  and  (4)  persistent  symptoms  despite
adequate anti-angina treatment and therapy for at
least one month with a double dose of omeprazole
(2 ￗ 20 mg). The exclusion criteria were as follows:
(1) changes in the ECG which make it impossible to
estimate ischaemic signs (e.g. left bundle branch
block or pre-excitation syndrome); and (2) the
taking of medicines which may affect gastric acid
secretion or digestive tract motility up to two weeks
prior to the examination, with the exception of the
ad  hoc  taking  of  nitroglycerine  tablets.  The
demographic and clinical data of the subjects
submitted for analysis are presented in Table I.
A panendoscopy was conducted using a video-
endoscope from OLYMPUS. Biopsy specimens from
the gastric corpus, angle and antrum were taken.
Hp  infection  was  diagnosed  on  the  basis  of
histology and/or a urease test in 33 (52%) patients.
In all Hp-positive subjects, eradication therapy with
omeprazole (2 ￗ 20 mg), amoxicillin (2 ￗ 1 g) and
metronidazole  (2  ￗ  500  mg)  for  14  days  was
recommended.  The  Hp  eradication  rate  was 
not  checked,  e.g.  by  using  a breath  test. 
After eradication therapy in all individuals, the
continuation of a double dose of omeprazole (i.e. 
2 ￗ 20 mg) was prescribed. In Hp-negative patients
a double dose of omeprazole (i.e. 2 ￗ 20 mg) as
monotherapy was recommended to start imme  -
diately  after  performance  of  the  diagnostic
procedure. Patients with CAD took their previously
recommended  standard  therapy,  i.e.,  at  least
acetylsalicylic acid, beta-blockers, angiotensin-
converting enzyme inhibitors or statins. 
Moreover, at the study beginning, in all patients,
besides gastroenterological work-up, a treadmill
stress test was performed. A clinically positive stress
test was observed in 17 (51%) Hp-positive subjects,
and in 16 (53%) Hp-negative subjects; 10 (30%) Hp-
positive and 4 (13%) Hp-negative individuals had
an electrocardiographically positive stress test
outcome (Table I). In none of the patients was
simultaneous occurrence of angina-like chest pain
and significant (≥ 1 mm) ST interval depression
observed. 
For the entire observation period, patients were
followed up in an outpatient clinic. However, in
order  to  obtain  reliable  and  objective  data,
information relating to the duration and causes of
hospitalization in the database of social security
numbers from the National Health Foundation
(NHF) was received on 30 September 2007. The
average observation period for the whole group of
subjects was 977 ﾱ249 days. As, fortunately, the
standard primary end points of death or myocardial
infarction did not occur during the observation
period,  hospitalization  due  to  acute  coronary
syndrome was established as the end point of the
analysis.  The  decisions  concerning  subjects’
hospitalization were taken independently of the
researcher by the doctors working in the emergency
rooms of the hospitals concerned. The main criteria
for  patients’  admissions  were  as  follows:  an
increase  in  chest  pain  frequency  and  strong,
retrosternal chest pain resistant to nitroglycerine
tablet application, which were not accompanied by
ischaemic ECG changes. All hospitalized patients
were diagnosed with unstable angina on discharge
and such information was reported to the NHF
(I.20.0 according to ICD-10 classification). The mean
hospitalization-free  period  in  the  admitted
individuals was 437 ﾱ356 days. 
The study protocol was approved by the local
Bioethics Committee of the Nicolaus Copernicus
University in Torun and Collegium Medicum in
Bydgoszcz, Poland. All subjects gave their informed
consent  prior  to  the  start  of  the  enrolment
procedures. All procedures have been conducted in
compliance with the Declaration of Helsinki. 
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
Statistical  analysis  was  conducted  using
a licensed  version  of  the  statistical  software
STATISTICA PL 8.0 for Windows. The results were
presented as the mean ﾱ the standard deviation
(SD) or n (%). The statistical significance of the
differences between Hp-infected and non-Hp-
infected patients was verified using an unpaired
Student’s t-test or one-tailed Fisher exact test
(Table I). Survival analysis was performed. The
Wilcoxon-Gehan test and Cox’s F test in the Kaplan-
Meier method for two and many groups and Cox
proportional hazard analysis were used. 
Results 
In 33 (52%) subjects, Hp infection was diagnosed
and eradication therapy recommended (Table I).
Within the 2.7-year observation period, 24/63 (38%)
subjects were hospitalized due to suspected acute
coronary  syndrome,  and  discharged  with  the
diagnosis of unstable angina (I.20.0 according to
ICD-10 classification). None of them died, presented
an increased level of cardiac troponin or needed
a rescue coronarography. Among the hospitalized
subjects, 14/24 (58%) had obstructive changes in
the  coronary  angiogram  made  before  the
observation period; 9/24 (37%) originated from the
Hp-positive group, and 15/24 (63%) came from the
Hp-negative group (p = 0.055). Therefore, patients
from the Hp-negative group, for whom eradication
therapy was not recommended, were borderline
more frequently hospitalized due to acute coronary
syndrome (15/30; 50%) than patients earlier treated
for  Hp  infection  (9/33;  27%),  despite  having
presented  a similar  percentage  of  significant76 Arch Med Sci 1, February / 2011
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coronary artery narrowing and even borderline
lower values of plasma lipids (Table I). 
Moreover, this analysis has shown that the
individuals who during gastroenterological work-
up  were  diagnosed  as  Hp-positive,  in  whom
eradication therapy at the beginning of the study
was recommended, had on average a longer period
without hospitalization due to acute coronary
syndrome than Hp-negative subjects (Table I). This
favourable  effect,  which  was  connected  with
a recommendation of eradication treatment in Hp-
positive subjects, was confirmed by their survival,
Kaplan-Meier analysis (Figure 1) and multi-factorial
analysis using the Cox proportional hazard model
(Table II). This analysis also showed that besides
a recommendation of Hp-eradication therapy, other
factors  connected  with  a delayed  risk  of
hospitalization due to acute coronary syndrome
were as follows: normal coronary angiogram or no
obstructive  changes  in  the  coronary  arteries;
a lower number of hospitalizations because of chest
pain in the period prior to the eradication therapy
recommendation; and female gender (Table II). 
The investigated group consisted of patients both
with  and  without  significant  coronary  artery
narrowing;  thus  the  common  effect  of  Hp-
eradication treatment and coronary angiogram on
the risk of hospitalization due to acute coronary
syndrome was additionally demonstrated (Figure 2).
The  defined  model  also  achieved  statistical
significance (ˇ2 = 9.7, p = 0.021), and patients with
an  eradication  therapy  recommendation  and
without significant coronary artery narrowing (Hp+
CAD–)  had  a significantly  lower  risk  of
hospitalization than Hp-negative subjects with
coronary artery disease (Hp– CAD+) (p = 0.048,
Cox’s F test) within the 2.7-year observation period. 
Discussion
In this analysis the outcome of a Hp eradication
therapy recommendation in patients with recurrent
angina-like chest pain, both with and without CAD,
was  investigated.  Its  statistically  significant
favourable influence on the duration of hospi  -
talization-free periods was confirmed both in basic
statistics  (Table  I)  and  in  advanced  statistical
V Va ar ri ia ab bl le e    H Hp p   ( (+ +) ), ,   n n = =   3 33 3 H Hp p   ( (– –) ), ,   n n = =   3 30 0 p p
Event-free period [days] 8 88 84 4   ﾱ ﾱ3 31 16 6 6 66 65 5   ﾱ ﾱ4 42 23 3 0 0. .0 02 2
Hospitalization because of acute coronary syndrome, n (%) 9 (27) 15 (50) 0.055
Time to the first hospitalization [days] – in hospitalized subjects only  573 ﾱ397 355 ﾱ314 0.15
Gender (male), n (%) 1 12 2   ( (3 36 6) ) 2 20 0   ( (6 67 7) ) 0 0. .0 02 2
Age [years] 5 52 2. .2 2   ﾱ ﾱ9 9. .0 0 5 56 6. .6 6   ﾱ ﾱ7 7. .3 3 0 0. .0 04 4
BMI [kg/m2] 27.9 ﾱ3.9 28.9 ﾱ4.9 0.46
WHR  0.94 ﾱ0.09 0.9 ﾱ0.08 0.11
Smoking, n (%) 5 (15) 1 (3) 0.19
Blood glucose [mg/dl]  100.0 ﾱ17.6 100.6 ﾱ11.6 0.93
Cholesterol [mg/dl]  216.6 ﾱ48.8 192.6 ﾱ39.0 0.08
HDL cholesterol [mg/dl]  49.5 ﾱ8.2 51.0 ﾱ15.5 0.70
LDL cholesterol [mg/dl]  135.1 ﾱ38.3 114.6 ﾱ15.5 0.08
Triglycerides [mg/dl]  162.4 ﾱ78.2 121.5 ﾱ58.2 0.07
History of myocardial infarction, n (%) 3 (9) 8 (27) 0.16
History of hypertension, n (%) 12 (36) 15 (50) 0.75
History of diabetes, n (%) 4 (12) 6 (20) 0.72
History of PCI, n (%) 7 (21) 7 (23) 0.53
History of CABG, n (%) 4 (12) 3 (10) 0.55
Esophagitis, n (%) 4 (12) 4 (13) 0.90
> 50% narrowing of coronary, n (%) 15 (45) 13 (43) 0.53
Angina-like chest pain during the stress test, n (%) 10 (30) 4 (13) 0,16
Significant ST interval depression ≥ 1 mm, n (%) 17 (51) 16 (53) 0,080
BMI – body mass index, WHR – waist to hip ratio, PCI – percutaneous coronary intervention, CABG – coronary artery bypass graft 
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methods, as well as in survival analysis, in two-
(Figure  1),  four-  (Figure  2)  and  multi-factorial
analyses (Table II). Factors other than Hp infection
delaying the occurrence of the defined end point
were as follows: normal coronary angiogram, female
gender, and less frequent hospitalization before
a gastroenterological chest pain work-up. Moreover,
patients  who  were  Hp-positive  at  the  study
beginning and were treated for Hp infection tended
to  be  less  frequently  admitted  due  to  acute
coronary syndrome during the whole observation
period. 
The majority of reference data seems to confirm
the results of my analysis, despite their being based
on  a mixed  subject  group  consisting  both  of
patients with normal coronary angiogram and those
with significant narrowing of the coronary arteries.
Some authors have reported a positive association
between Hp infection, especially with CagA-positive
strains and cardiac syndrome X [19, 20], and acute
coronary syndromes [13, 14], although some have
not  confirmed  this  [21,  22,  31].  Moreover,  the
majority of physicians working in the Asia-Pacific
region believe that Helicobacter pylori plays a role
in NCCP pathogenesis [32]. The eradication of Hp,
similarly to my study, was an effective treatment
for patients with reflux-related NCCP after a 12-
month follow-up [33]. Nocente et al. reported a case
of a 42-year-old man with cardiac syndrome X in
whom symptoms resolved after Hp eradication [34],
and  Kowalski  et  al.  [24,  25]  confirmed  by
angiography  a decrease  in  coronary  artery
narrowing after a 6-month observation period
following Hp-eradication therapy. 
The  advantage  revealed  in  this  study  of
eradication therapy with subsequent treatment
with PPIs over therapy with PPIs alone in patients
with recurrent chest pain might be explained in
more than one way. Firstly, therapy with antibiotics
might lead to a decrease in total pathogen burden
[26],  which  might  cause  a reduction  in  the
connected systemic inflammatory response and
both an improvement in endothelial function [20]
and a decrease in oesophagitis activity [7]. Secondly,
the recommendation of Hp-eradication therapy
0 200 400 600 800 1000 1200 1400 1600
d da ay ys s
F Fi ig gu ur re e   1 1. . Comparison of two Kaplan-Meier curves as
a function of time to the first hospitalization due to
acute coronary syndrome in Hp-infected patients
and those without signs of infection (Wilcoxon-
Gehan test, F = 2.33, p = 0.020; Cox’s F test = 1.96;
p = 0.049). The number of subjects in active follow-
up in respective groups at the beginning and end of

































































































































































































I In nd de ep pe en nd de en nt t   v va ar ri ia ab bl le e    B Be et ta a S St ta an nd da ar rd d   e er rr ro or r p p
Number of hospitalizations before gastrological diagnostic performance  – –0 0. .2 22 2 0 0. .0 08 8 0 0. .0 00 08 8
Hp-eradicative treatment recommendation  1 1. .1 18 8 0 0. .5 59 9 0 0. .0 04 45 5
Significant > 50% coronary vessel narrowing  – –1 1. .4 45 5 0 0. .6 67 7 0 0. .0 03 3
History of myocardial revascularization  –0.94 0.65 0.15
Gender (male/female)  – –1 1. .5 55 5 0 0. .7 74 4 0 0. .0 04 4
Canadian Cardiovascular Society classification (II or III) 0.32 0.70 0.65
History of myocardial infarction  –0.25 0.80 0.76
Hypertension  0.49 0.85 0.56
Diabetes mellitus  –0.05 0.73 0.95
Age  0.06 0.04 0.14
BMI  0.10 0.09 0.26
WHR  –8.89 5.56 0.11
LDL cholesterol  –0.01 0.01 0.32
Hp – Helicobacter pylori, BMI – body mass index, WHR – waist to hip ratio 
T Ta ab bl le e   I II I. .   Cox Proportional Hazard Regression Model for the number of days to the first hospitalization due to suspected
acute coronary syndrome (ˇ2 = 30.40; p = 0.008)78 Arch Med Sci 1, February / 2011
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might have a psychological effect. The psychological
aspect  of  chest  pain  recurrence  has  been
underlined in a number of papers, concerning not
only individuals with NCCP and a normal coronary
angiogram, but also patients with CAD [8, 9, 35, 36].
Among  the  Polish  population  in  general,  Hp
infection is recognized as a common cause of
a number of symptoms, probably due to the high
overall infection rate, which amounts to 73%, and
in subjects over 25 years of age to 85-95% [37]. In
the studied population, Hp prevalence was lower
(52%). However, because Hp infection is associated
with increased consultation due to GERD and/or
dyspepsia [38], the potential elimination of the
microorganism due to recommended eradication
therapy might have a favourable effect. Thirdly, the
potential elimination of Hp might have an effect on
autonomic nervous system balance and might lead
to an increase in the pain threshold, secondary
changes in gastric acid secretion, oesophageal
motility, and the degree of oesophagitis severity 
[2, 4, 7, 39]. 
My observations, like many others, have some
limitations. Firstly, the study group was relatively
small. However, on the PubMed database I could find
only a few works concerning the gastroenterological
aspects of chest pain with a number of subjects
greater than in my study. The number of subjects in
my study was sufficient to show a significant effect
of eradication treatment in a comparison of the two
groups  (Figure  1),  although  not  adequate  to
demonstrate this effect in a comparison of four
groups (Figure 2). Regardless, I hope that my results
present a sufficient premise for planning further
study. Secondly, my subjects were not randomized
for eradication therapy, which could lead to some
selection  bias  and  some  baseline  differences
between the Hp-positive and Hp-negative group
(Table I), which might influence the difference in
outcome. However, the analysis included consecutive
non-selected patients referred to the clinic by leading
doctors,  independent  of  the  researcher,  who
suspected a noncardiac origin of symptoms in their
patients independently of coronary artery status.
Moreover, in both Hp-infected and non-Hp-infected
groups, the presence of infection was checked using
the same diagnostic methods. Thirdly, the study
design was not double-blind and placebo-controlled,
but was primarily planned as an observational, not
interventional, investigation. Moreover, the ran  -
domization of Hp-infected, symptomatic patients to
eradication therapy might evoke ethical doubts.
Fourthly, the established end point of this study may
be recognized as highly subjective and difficult to
determine precisely. However, because the classical
primary end point did not, fortunately, occur in any
of the patients, choosing other, more usual, end
points was not possible. Moreover, any decisions
concerning patient hospitalization and establishment
of the discharge diagnosis did not depend on the
investigator but on the independent physicians
working in the admission rooms and cardiology units
of the hospitals concerned. On the one hand, this
might be a source of bias, but on the other provides
apparent  random  selection.  In  my  opinion,  the
potential bias of my investigation was also reduced
by the estimation of the eradication treatment effect
just after obtaining data from the NHF. Fifthly, the
investigated population was heterogeneous and
consisted  of  patients  both  with  and  without
significant coronary artery narrowing, and patients
infected by Hp were younger and less frequently
were of the male gender (Table I). However, the
primary aim of this analysis was to compare the
outcome of diagnostic and therapeutic procedures
in patients with recurrent chest pain, suspected of
being noncardiac in origin and non-responsive to
double  doses  (i.e.  2  ￗ  20  mg)  of  omeprazole.
Moreover, this limitation was diminished by the use
of multi-factorial statistical analysis. The precise
selection of patients into a homogeneous group
could be planned for further study. Sixthly, the
efficacy of Hp-eradication therapy was not checked,
so it is not known if treating patients resulted in Hp
being eradicated and if the revealed observations
were  an  effect  of  the  therapy  alone  or  of
microorganism eradication. However, the studied
patients have no clinical indications regarding such
procedures according to Polish recommendations [1];
the  outcome  of  eradication  therapy  was  not
a primary  end  point  of  the  analysis;  and  its
0 200 400 600 800 1000 1200 1400 1600
d da ay ys s
F Fi ig gu ur re e   2 2. .   Comparison of four Kaplan-Meier curves as
a function of time to the first hospitalization due to
acute  coronary  syndrome  in  patients  divided
according to signs of Hp infection (positive Hp+ or
negative  Hp-)  and  significant  coronary  artery
narrowing (CAD+ or CAD–) (ˇ2 = 9.7; p = 0.021). The
number of subjects in active follow-up in respective
groups at the beginning and end of the study is
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favourable effect was found by chance, simply during
analysis after receiving data from the NHF. 
In  conclusion,  in  this  preliminary  study  Hp
eradication therapy was one among a number of
independent factors prolonging the time to the first
hospitalization due to acute coronary syndrome in
patients with recurrent angina-like chest pain non-
responsive  to  treatment  with  PPIs.  A further,
randomized and placebo-controlled investigation in
a greater number of patients is needed regarding
this observation. 
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